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Abstract
Background: The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) was established in
2008 to answer strategic questions about schistosomiasis control. For programme managers, a high-priority
question is: what are the most cost-effective strategies for delivering preventive chemotherapy (PCT) with
praziquantel (PZQ)? This paper describes the process SCORE used to transform this question into a harmonized
research protocol, the study design for answering this question, the village eligibility assessments and data resulting
from the first year of the study.
Methods: Beginning in 2009, SCORE held a series of meetings to specify empirical questions and design studies
related to different schedules of PCT for schistosomiasis control in communities with high (gaining control studies)
and moderate (sustaining control studies) prevalence of Schistosoma infection among school-aged children. Seven
studies are currently being implemented in five African countries. During the first year, villages were screened for
eligibility, and data were collected on prevalence and intensity of infection prior to randomisation and the
implementation of different schemes of PZQ intervention strategies.
Results: These studies of different treatment schedules with PZQ will provide the most comprehensive data thus
far on the optimal frequency and continuity of PCT for schistosomiasis infection and morbidity control.
Conclusions: We expect that the study outcomes will provide data for decision-making for country programme
managers and a rich resource of information to the schistosomiasis research community.
Trial registration: The trials are registered at International Standard Randomised Controlled Trial registry (identifiers:
ISRCTN99401114, ISRCTN14849830, ISRCTN16755535, ISRCTN14117624, ISRCTN95819193 and ISRCTN32045736).
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Background
The Schistosomiasis Consortium for Operational Research
and Evaluation (SCORE) was established through a grant
provided to the University of Georgia (UGA) Research
Foundation from the Bill & Melinda Gates Foundation in
December 2008, to answer strategic questions about schis-
tosomiasis control and elimination. SCORE’s focus is on
operational research that will enhance the effectiveness of
current and future schistosomiasis control programmes
[1]. The SCORE portfolio includes evaluation of screening
tests for Schistosoma mansoni [2, 3]; development of a
gold-standard diagnostic test for S. mansoni and Schisto-
soma haematobium [4, 5]; assessment of the impact of
drug pressure on parasite genetics [6]; research related to
snail control [7]; the “rapid answers project” (RAP), which
synthesises existing data to answer important program-
matic questions; and studies on elimination of S. mansoni
and S. haematobium in areas of very low prevalence [8, 9].
It also includes large field studies to compare multi-year
strategies for preventive chemotherapy (PCT) in areas
with moderate and high prevalence of schistosomiasis
[1, 10]. This paper describes the decision-making process
that informed the study design for these gaining and sus-
taining schistosomiasis control programmes that are facili-
tated by a series of cluster randomised trials with different
PCT schemes. We present the results of eligibility assess-
ments and year 1 data collection within 825 villages in five
African countries where the studies are being conducted.
The prevalence of schistosome infection is usually high-
est in school-aged children (SAC) [11–15]. More than
90 % of schistosome infections occur in sub-Saharan Africa
[16–18], resulting in at least 3.3 million disability-adjusted
life years (DALYs) due to schistosomiasis-associated clin-
ical and subtle morbidities [16, 19]. The World Health
Organization (WHO) treatment guidelines call for PCT
mainly targeting SAC in endemic areas through periodic
administration of praziquantel (PZQ) [20], either through
school-based treatment (SBT) or community-wide treat-
ment (CWT) [1, 21–25]. The SCORE studies of gaining
and sustaining control of schistosomiasis will compare the
impacts and costs of different multi-year strategies involv-
ing CWT, SBT and “drug holidays” (i.e. years without
PCT). Information from this research is expected to inform
programme managers of national disease control pro-
grammes about the most effective strategies for gaining
and sustaining the control of schistosomiasis and might
also inform strategic shifts from morbidity control to inter-
ruption of transmission, therefore local elimination.
Methods
Process for designing SCORE’s operational research on
gaining and sustaining control of schistosomiasis
In April 2009, SCORE convened a meeting involving re-
searchers, programme managers and representatives of
WHO to design the gaining and sustaining control stud-
ies. Discussions included the role of mapping, the need
to integrate SCORE operational research with ongoing
government programmes, integration of schistosomiasis
control with other neglected tropical disease (NTD)
prevention and control efforts (mainly soil-transmitted
helminthiasis and lymphatic filariasis), data management
for multi-country studies and concerns about ensuring the
effectiveness and sustainability of PCT. It was decided that
the studies would be large-scale cluster randomised trials
in areas with starting prevalence of ≥10 % in SAC. In-
terventions would occur once a year, except in villages
on “PZQ holiday” years, during which no drug adminis-
tration will occur. Data would be collected annually, ex-
cept in villages on “drug holiday” that year, starting
before the first round of PCT and ending in the year
after the fourth treatment round.
Based on this input, SCORE developed a request for
proposals, which was disseminated to teams with a his-
tory of conducting relevant population-based helminth-
iasis research in Africa. Teams could propose to conduct
studies of gaining control of S. haematobium (Sh2) or S.
mansoni (Sm2), respectively, in areas with prevalence
among SAC of ≥25 % or sustaining control (Sh1 or Sm1
studies, respectively) in areas with prevalence ranging
between 10 and 24 %. Five study teams, each consisting
of a principal investigator (PI) from the country where
the study would take place and a northern partner, were
selected to participate (Table 1). Criteria for selecting
teams included likelihood that the proposed study areas
would have sufficient numbers of villages meeting inclu-
sion criteria, experience and track record of the team and
proposed approach to ensuring high coverage of PCT.
Mozambique and Niger were funded to conduct stud-
ies of S. haematobium, while Côte d’Ivoire, Kenya and
Tanzania were funded to conduct studies of S. mansoni.
Two teams (in Kenya and Niger) were funded to con-
duct studies of both gaining and sustaining control; in
both countries gaining and sustaining studies occurred
in separate areas. Côte d’Ivoire was funded to conduct a
sustaining control study [26], and Mozambique and
Tanzania were each funded to conduct gaining control
studies (Table 1).
After being selected, the study teams participated in a
“harmonization meeting” to review and refine the proto-
col. Protocols were standardised and plans were developed
to ensure that data from comparable sites could be com-
bined in subsequent analyses. In addition to finalising the
study design and sample sizes, investigators agreed to a
number of process measures and activities that were
deemed essential for a successful study. These included
robust plans for community sensitization, a commitment
to measure coverage after each round of PCT and a will-
ingness to revisit communities that did not achieve the
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coverage target to treat people who had been missed.
Major discussion points and decisions from the initial and
harmonization meetings are described in Table 2.
Study design
Figure 1 shows the treatment arms for the gaining (n = 6
arms) and sustaining (n = 3 arms) control studies. The
most intensive intervention arm in the gaining control
studies involves four years of CWT, while the least in-
tensive intervention arm involves two years of SBT alter-
nating with “PZQ holiday” years. For sustaining control,
the most intensive intervention arm involves four years
of SBT, while the least intensive arms involve two years
of SBT followed by two “PZQ holiday” years. The pattern
of interventions in the three arms in the sustaining control
studies matches that of arms 4, 5 and 6 in the gaining con-
trol studies.
A simple random allocation approach was used to as-
sign all eligible villages to study arms except in Niger,
where, in contradiction to the harmonized protocols, geo-
graphically clustered groups of 25 villages were randomly
assigned to study arms.
The number of villages per arm and number of 9- to
12-year-old children tested per village were based on
sample size calculations and practical considerations.
Power computations were based on generalized estimat-
ing equations used to fit a logistic regression model that
included treatment arm and time effects and treatment-
by-time interaction, and assumed an over-dispersion
parameter of φ = 5.0. Year 1 infection prevalence was as-
sumed to be 50 % for gaining control studies and 25 %
for sustaining studies. We assumed that the most intense
treatment (arm 1) would reduce prevalence to a specific
target level (15 and 10 % for gaining and sustaining con-
trol studies, respectively) by study end. We computed
minimum effect sizes (difference between arm 1 and an
alternative treatment arm at study conclusion) that
could be detected with 90 % power for a two-sided α =
0.05 level test. Separate computations were carried out
using various numbers of villages per treatment arm and
children sampled per village. We assumed negligible cor-
relation between measurements in year 1 and at study
conclusion. Based on these assumptions, we estimated
that 25 villages per treatment arm and 100 children aged
9–12 years per village were sufficient to detect absolute
treatment differences of 11.4 and 9.4 % at the conclusion
of the gaining and sustaining studies, respectively.
In addition to children aged 9–12 years, in the first
and final fifth year, the protocol includes testing up to
100 children aged 5–8 years in both gaining and sustain-
ing studies, and testing of 50 adults (aged 20–55 years)
in the first and fifth years of the gaining studies. Popula-
tions to be tested in the different study years and
methods of testing are shown in Table 3. No testing was
to be conducted during “PZQ holiday” years because
children found positive would need to be treated, and if
the village prevalence was very high, it might be unethical
to not treat the whole village.
Table 1 Study sites, study teams and numbers of villages screened in the eligibility surveys
Type of
study
Country Region of the country Lead African partner institution Lead Northern partner
institution
# villages
screened
# (%) villages
that met criteria
Sustaining
control
Côte d’Ivoire
(Sm1)
Région des Montagnes
and Région du Moyen
Cavally
Université Félix Houphouët-Boigny;
Abidjan, Côte d’Ivoire
Swiss Tropical and Public
Health Institute; Basel,
Switzerland
263 77 (29.3)
Kenya (Sm1) Kisumu region in
western Kenya bordering
Lake Victoria
Center for Global Health Research,
Kenya Medical Research Institute
(KEMRI); Nairobi, Kenya
Centers for Disease Control
and Prevention (CDC);
Atlanta, USA
150 75 (50.0)
Niger (Sh1) Dosso and Tillaberi
regions in western Niger
Réseau International Schistosomoses,
Environnement, Aménagement et
Lutte (RISEAL-Niger), Niamey, Niger
Schistosomiasis Control
Initiative (SCI), Imperial
College London; London, UK
150 75 (50.0)
Gaining
control
Kenya (Sm2) Kisumu region in western
Kenya bordering Lake
Victoria
Center for Global Health Research,
KEMRI; Nairobi, Kenya
CDC; Atlanta, USA 320 150 (46.9)
Mozambique
(Sh2)
Cabo Delgado province
in northern Mozambique
Catholic University of Mozambique;
Beira, Mozambique
SCI, Imperial College
London; London, UK
150 150 (100.0)
Niger (Sh2) Dosso and Tillaberi
regions in western Niger
National NTD Programme, Ministry
of Health, Niamey, Niger
SCI, Imperial College
London; London, UK
248 150 (60.5)
Tanzania
(Sm2)
Mwanza region
bordering Lake Victoria
Mwanza Research Center, National
Institute for Medical Research
(NIMR); Mwanza, Tanzania
University of Copenhagen;
Copenhagen, Denmark
308 167 (50.9)
Total 1,569 767 (48.3)
Sh1 sustaining control study in S. haematobium moderate endemicity villages, Sh2 gaining control study in S. haematobium high endemicity settings,
Sm1 sustaining control study in S. mansoni moderate endemicity villages, Sm2 gaining control study in S. mansoni high endemicity villages
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Eligibility surveys
To be eligible for inclusion in the five-year study, a village
had to have a primary school (so that it could be rando-
mised to SBT), at least 100 children aged 9–12 years and
a starting prevalence of Schistosoma infection in the
appropriate range (≥25 % for gaining and 10–24 %
for sustaining control studies). Fifty children aged 13–14
years were tested in potentially eligible villages until the
required number of villages (150 for gaining and 75 for
sustaining control) were found. S. mansoni was assessed
in these eligibility surveys by examining two slides from
one stool sample per child using the Kato-Katz method
[27], while S. haematobium was evaluated by microscopic
examination of filtered urine or reagent strip testing
for microhaematuria on a single mid-day urine speci-
men [13–15].
Laboratory methods
For the eligibility surveys that involved children aged
13–14 years and for prevalence and intensity evaluations
in adults and children 5–8 years of age, S. mansoni in-
fection was based on microscopic examination of dupli-
cate Kato-Katz thick smears from a single stool
specimen [27]. For the annual cross-sectional prevalence
and intensity assessment of S. mansoni in 9- to 12-year-
old children, stool specimens were collected on three
Table 2 Key decisions related to design of the gaining and sustaining control of schistosomiasis studies, and their rationale
Decision Rationale
The study arms would not necessarily align with WHO
recommendations for PCT
The WHO recommendations are not solidly evidence-based, and studying them
would not answer most pressing questions
Sustaining schistosomiasis control studies would only involve
SBT, and not adults or CWT
Existing data indicate adults are not major sources of transmission when
prevalence of infection is <25 %, making testing and interventions for adults not
cost-effective when resources are limited
Sustaining and gaining control of schistosomiasis studies would
involve places with prevalence 10–24 % and ≥25 % in children
aged 9–12 year, respectively
The cutoff of 10 % for sustaining studies was based on the idea that below that,
one is moving towards elimination, and this will require additional interventions
besides PCT. The choice of 25 % prevalence to divide gaining and sustaining
studies was based on expert opinion
Sustaining control of schistosomiasis studies would include
three arms, gaining studies would have six arms
SCORE would have preferred to test many more combinations of interventions,
however this was not practical. The numbers of arms, numbers of villages per
arm and number of children per village were an attempt to balance scientific,
resource-related and practical considerations
Children aged 13–14 years would be tested to determine
eligibility of a village for the sustaining or gaining control of
schistosomiasis studies
Children who test positive must be treated. Testing children aged 9–12 years
and treating those infected could affect the year 1 and subsequent study
results, especially if prevalence is high. A very high prevalence could necessitate
treating the entire village
“Drug holidays” would be included in study arms The cost and impact of “drug holidays” is not known. If holidays have minimal
negative effects on prevalence and intensity of Schistosoma infection in villages that
have been targetted by PCT, holidays could allow for more widespread treatment
In all studies, first-year students would be tested at the beginning
and end of the study
First-year students provide a measure of new infections in the community. If
transmission is decreasing, prevalence and intensity in these children should fall
A convenience sample of adults would be tested in gaining
control of schistosomiasis studies
Although initial plans called for a more systematic approach to identifying adults
for testing, this proved impractical given the resources, so convenience samples
were allowed
SCORE would provide mobile data collection software Information provided at the harmonization meeting indicated that the software
being used in lymphatic filariasis research could be readily adapted for SCORE
use. This turned out not to be the case, but SCORE’s commitment to
standardising data collection, providing support for data cleaning and storage
and supporting mobile technology remained
SCORE-supported research needed to be conducted in close
collaboration with Ministries of Health and Education
This was deemed essential both to ensure that PCT in SCORE study areas were
conducted per protocol and to encourage the Ministries to use the results. In
addition, it was assumed that PZQ access and use would work best when
coordinated with the national schistosomiasis control programme
Study villages would need to achieve high levels of coverage; if
these were not achieved during PCT, a team would need to
return to the village to provide additional treatment
It was recognised that high coverage levels are not always achieved by PCT
programmes. However, comparison of effectiveness among arms would require
that treatments be delivered and actually consumed. Investigators were
encouraged to have treatments directly observed to assure compliance
Investigators would be encouraged to publish their countries’
results; the SCORE secretariat would take responsibility for
publishing combined results
In addition to encouraging widespread dissemination of the results of research,
data sharing approaches that would allow investigators to use the data for
modelling and other purposes were to be developed
CWT community-wide treatment, PCT preventive chemotherapy, PZQ praziquantel, SBT school-based treatment, SCORE schistosomiasis consortium for operational
research and evaluation, WHO World Health Organization
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consecutive days from each child, and eggs enumerated
on duplicate Kato-Katz thick smears per specimen.
The eligibility surveys assessed S. haematobium in-
fection by either urine filtration microscopy [28, 29] or a
reagent strip assay for microhaematuria [30] on a single
urine specimen. For the cross-sectional prevalence and
intensity surveys, two 10-ml aliquots from a single
mid-day urine specimen were filtered, and the filters
examined quantitatively under a microscope by two
independent experienced laboratory technicians for S.
haematobium eggs.
Data collection and management
SCORE provided a list of variables to be collected on in-
dividual participants, as well as standard operating pro-
cedures (SOPs) for diagnosing schistosomiasis. Forms
for collecting village-level data on such factors as water
and sanitation, occupations and other contextual factors
that might affect study results were also provided.
Most year 1 data were collected on paper. Kenya,
Mozambique and Tanzania used a mobile-based system
(EpiCollect®) developed at Imperial College London for
data collection. Côte d’Ivoire used a mobile-based system
(LINKS®) developed at the Task Force for Global Health
for some data collection beginning in year 2. These systems
involve data entry on-site, synching of data to a central ser-
ver and downloading of data for cleaning and analysis.
Statistical analysis
Simple univariate and bivariate analyses were used to de-
scribe study participant demographics. Differences in in-
fection prevalence and intensity by study arm were
assessed using logistic and Poisson regression models, re-
spectively, with adjustment for over-dispersion. Calcula-
tions of infection intensity included only those individuals
who had at least one positive slide; for those, intensity was
the geometric mean on all their slides, including those
without Schistosoma eggs detected.
Fig. 1 a Study arms and timeline for the studies of gaining control of schistosomiasis in Africa. CWT, community-wide treatment; SBT, school-based
treatment; Sm2, gaining control study in S. mansoni endemic villages; Sh2, gaining control study in S. haematobium endemic villages. b Study arms
and timeline for the studies of sustaining control of schistosomiasis in Africa. SBT, school-based treatment; Sh1, sustaining control study in S.
haematobium endemic villages; Sm1, sustaining control study in S. mansoni endemic villages
Table 3 Populations tested in gaining and sustaining control of schistosomiasis studies, and microscopy performed, by year of the study
Intended population tested per village Microscopy performed Year 1 Years 2–4 Year 5
100 children aged 9–12 years One mid-day urine specimen subjected to two filtrations; or three
stool specimens subjected to duplicate Kato-Katz thick smears
Gaining and
sustaining
Gaining and
sustaining
Gaining and
sustaining
100 (or as many as possible)
children aged 5–8 years
One mid-day urine specimen subjected to two filtrations; or one
stool specimen subjected to duplicate Kato-Katz thick smears
Gaining and
sustaining
Gaining and
sustaining
Adults One mid-day urine specimen subjected to two filtrations; or one
stool specimen subjected to duplicate Kato-Katz thick smears
Gaining Gaining
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Ethics statement
Written informed consent was obtained from adults (in-
cluding parents/legal guardians of children in the study)
and assent was obtained from children less than 18 years
old, except in places where village-level consent is the
standard, in which case local requirements were met.
Ethical review of research protocol was implemented by
human subjects committee in each African country and
by the institutional review board (IRB) of their respective
northern partners. Sm1 and Sm2 studies in Kenya were
reviewed and approved by the National Ethics Review
Committee of the Kenyan Medical Research Institute
(KEMRI; approval numbers SCC 1800 and SCC 1820,
respectively) and by the IRB of the Centers for Disease
Control and Prevention (CDC; approval #: 1661). For
the Sm1 study in Côte d’Ivoire, ethical approval was
obtained from the ethics committees in Côte d’Ivoire
(reference no. 1994MSHP/CNER) and Basel (reference
no. EKBB 279/10). In Niger, ethical approval was ob-
tained from the Niger Republic National Consulate
for ethical review (reference no. 012/2010/CCNE) and
from the Imperial College Research Ethic Committee
(ICREC_8_2_2). In Mozambique, ethical approval was
received from the Ministry of Health (reference no.
235/CNBS/10) and the Imperial College Research Ethic
Committee (ICREC_10_8_2). In Tanzania, ethical approval
was obtained from the National Institute for Medical
Research (NIMR; reference no. NIMR/HQ/R.8a/Vol.
IX/1022). In addition to these, the UGA IRB implemented
an administrative human subjects review and issued add-
itional approval per country’s protocol as follows: 10021–0,
10221–0, 10267–0, 10353–0, 10431–0 and 10533–0 for
Côte d’Ivoire, Kenya Sm1, Kenya Sm2, Tanzania, Niger and
Mozambique, respectively.
The trials have been registered with the Inter-
national Standard Randomised Controlled Trial registry
under ISRCT numbers 99401114 (Côte d’Ivoire), 14849830
(Kenya Sm1), 16755535 (Kenya Sm2), 95819193 (Tanzania),
32045736 (Niger), and 14117624 (Mozambique).
Results
Eligibility surveys
Investigators in the gaining control studies (Fig. 1a) had
to test between 150 and 320 villages to identify the 150
eligible villages; for sustaining studies, between 150 and
263 villages were surveyed to find 75 eligible villages
(Table 1). The most common reason for excluding
villages was that the prevalence among 13- to 14-year-
old children was out of range. In addition, 20 villages in
the Tanzania gaining studies were excluded because they
had high rates (>10 %) of mixed S. haematobium and S.
mansoni infections. Based on the added complexity of
analysis and significant increases in funding required for
testing to include areas with predominantly mixed infec-
tions, such settings were considered beyond the scope of
the current SCORE study design.
Year 1 surveys
Studies of gaining control (Kenya, Tanzania, Mozambique
and Niger)
Studies of gaining control (Fig. 1b) in S. mansoni areas
bordering Lake Victoria in the Kisumu region of western
Kenya and Mwanza region of Tanzania included 11,541
and 14,620 children aged 9–12 years, respectively
(Table 4). The prevalence of S. mansoni infection among
children aged 9–12 years was 62.7 % in Kenya and 55.5 %
in Tanzania. Among children aged 9–12 years, 7.3 % of
villages in Kenya and 20.3 % of villages in Tanzania had a
prevalence less than 25 %, despite prevalence ≥25 % in the
eligibility survey. Numbers of children between 9 and
12 year of age enrolled per village ranged from 12 to
101 in Kenya, and from 11 to 122 in Tanzania. There
were no significant differences in prevalence of infec-
tion or intensity among 9- to 12-year-old children by
study arm in either country (Fig. 2).
Studies of gaining control of S. haematobium in Cabo
Delgado province of northern Mozambique and the
Dosso and Tillaberi regions of western Niger enrolled
7317 and 14,249 children aged 9–12 years, respectively
Table 4 Numbers of participants and prevalence in the year 1 survey, by study type and country
Age group Variable Study - country
Sm2 - Kenya Sm2 - Tanzania Sh2 – Mozambique Sh2 – Niger Sm1 - Côte d’Ivoire Sm1 - Kenya Sh1 - Niger
5–8 years Number enrolled 4,725 12,359 7,463 13,553 4,812 1,609 6,667
Prevalence (%) 35.7 38.5 63.1 24.0 5.3 5.8 3.3
9–12 years Number enrolled 11,541 14,620 7,317 14,249 7,410 4,614 6,682
Prevalence (%) 62.7 55.5 66.6 21.3 20.9 17.7 4.2
Adults
(20–55 years)
Number enrolled 7,107 4,922 4,259 7,041 N/A N/A N/A
Prevalence (%) 44.7 28.1 44.8 11.3 N/A N/A N/A
Total Number enrolled 23,373 31,901 19,039 34,843 12,222 6,223 13,349
N/A not assessed, Sh1 sustaining control study in S. haematobium endemic villages, Sh2 gaining control study in S. haematobium endemic villages, Sm1 sustaining
control study in S. mansoni endemic villages, Sm2 gaining control study in S. mansoni endemic villages
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(Table 4). The prevalence of S. haematobium infection
was 66.6 % in Mozambique and 21.3 % in Niger. Ap-
proximately 5.3 % of villages in Mozambique and 67.3 %
in Niger had prevalence less than 25 % in this age group,
despite having had a prevalence ≥25 % among 13–14
year olds in the eligibility survey. The number of 9- to
12-year-old children enrolled per village ranged from 10
to 139 and from 51 to 149 in Mozambique and Niger,
respectively. Both the prevalence and intensity of infection
were similar among study arms (Fig. 2) in Mozambique.
However, the S. haematobium infection prevalence was
significantly different by study arms in Niger (p <0.001)
(Fig. 2). Infection prevalence was lower among children
aged 5–8 years and among adults, compared to children
aged 9–12 years, in Kenya, Tanzania, Mozambique and
Niger. However, in Niger Sh2 (Table 4), infection preva-
lence was slightly higher among younger children (24.0 %)
than among those aged 9–12 years (21.3 %).
Studies of sustaining control (Côte d’Ivoire, Kenya and Niger)
Studies of sustaining control in S. mansoni areas (Fig. 1b)
included 7410 children aged 9–12 from Région des
Montagnes and Région du Moyen Cavally in western
Côte d’Ivoire and 4614 from Kenya (Table 4). The preva-
lence among these children was 20.9 % in Côte d’Ivoire
and 17.7 % in western Kenya, near Lake Victoria, in an
area distinct from that where the gaining control study
was being conducted. In the baseline data on 9- to 12-
year-old children, 43 % (n = 32) of villages in Côte d’Ivoire
and 39 % (n = 29) in Kenya had year 1 prevalence outside
the desired range of 10–24 %. Nine (12 %) Ivorian and 14
(19 %) Kenyan villages had infection prevalence <10 %
and 23 (31 %) Ivorian and 15 (20 %) Kenyan villages had
infection prevalence ≥25 %. The number of children aged
9–12 years enrolled per village ranged from 77 to 115 in
Côte d’Ivoire and from 26 to 123 in Kenya. There were no
significant differences in prevalence or intensity of S. man-
soni infection by study arm in either country (Fig. 3). Adults
were not recruited into studies of sustaining control.
Sustaining control studies of S. haematobium in Niger
enrolled 6682 children aged 9–12 years from the Dosso
and Tillaberi regions of western Niger, with a prevalence
of infection of 4.2 % (Table 4). About 92 % of villages in
Niger had year 1 prevalence outside the desired range of
10–24 %, mostly less than 10 %. The number of children
enrolled per village ranged from 24 to 102 with 46
(61 %) of villages achieving the protocol enrollment
target of 100. There were no significant differences in
prevalence and intensity of S. haematobium infection
by study arm in Niger (Fig. 3) (p = 0.122 and p = 0.111, re-
spectively). Prevalence of infection among children aged
5–8 years was 3.3 % (Table 4).
Discussion
The SCORE gaining and sustaining control studies are
large operational intervention studies, involving complex
Fig. 2 Baseline infection prevalence and intensity for gaining control of schistosomiasis studies, by study arm. Figures depict box plots. Horizontal
lines in box interiors indicate medians. Box lengths represent the interquartile range (i.e. amount of data between the 75th and 25th percentile),
+ signs in boxes represent mean infection intensity (in eggs per gram of faeces (for S. mansoni) or per 10 ml of urine (for S. haematobium)) or
prevalence in the respective arms 1–6 and the whiskers represent the minimum and maximum infection prevalence or intensity. Sh2, gaining
control study in S. haematobium villages; Sm2, gaining control study in S. mansoni endemic villages
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coordination among multiple investigators from many
countries, between research projects and national schisto-
somiasis control programmes (often integrated within a
broader NTD master plan), and among national and sub-
national governmental levels and in-country community-
based and non-governmental organisations. In year 1
alone, the project enrolled 66,433 children aged 9–12
years across 825 villages in five countries, in addition to
large numbers of younger children (5–8 years) and adults
(20–55 years). Despite these large numbers, enrolment in
the year 1 study was somewhat lower than the expected
82,500. Possible reasons for this discrepancy include low
school enrolment, lack of parental consent, limited pre-
study sensitization in some areas, and flooding, political
unrest and other contextual issues extraneous to the
study. In addition to the logistical challenges of visiting 75
or 150 villages in each study, consenting and enrolling
large numbers of people, and the demands of laboratory
testing were considerable. The gaining and sustaining con-
trol surveys of S. mansoni were particularly difficult, re-
quiring duplicate assessment of three consecutive stool
specimens from children in the 9–12 year age group, as
well as duplicate testing of a single stool specimen in
young children and adults. For example, in the first year
alone 214,122 Kato-Katz thick smears were read for the
38,185 enrolled children aged 9–12 years. Technicians
read an additional 77,351 Kato-Katz thick smears from
the 35,555 enrolled young children and adults. By design,
the number of stools used for infection assessment dif-
fered by age-group and may in part explain the difference
in the prevalence of infection between age-groups as pre-
viously reported [31].
The SCORE gaining and sustaining schistosomiasis
control project made a dedicated effort as part of study
planning activities to identify eligible villages with suffi-
cient numbers of children for the respective studies. In
all countries but Mozambique, many more villages had
to be visited than anticipated to identify the number of
potentially eligible villages for this study. This suggests
that the historical data used to identify study areas was
outdated or unreliable, which might be partially ex-
plained by escalating control efforts [32]. Despite eligi-
bility survey prevalence in 13- to 14-year-old children
that met study criteria (range: 10–24 %), on testing in
year 1 of the actual study, 57.8 % of villages of eligible
villages in the sustaining studies had prevalence below
10 % or above 24 % among children aged 9–12 years. In
the gaining control studies, 26 % of villages with preva-
lence ≥25 % in the eligibility survey had prevalence
levels <25 % in 9- to 12-year-old children in year 1 of
the study. Possible explanations for the discordance be-
tween the eligibility and the year 1 survey results include
Fig. 3 Infection prevalence and intensity for sustaining control of schistosomiasis studies, by study arm. Figures depict box plots. Horizontal lines
in box interiors indicate medians. Box lengths represent the interquartile range (i.e. amount of data between the 75th and 25th percentile), + signs
in boxes represent mean infection intensity (eggs per gram of faeces (for S. mansoni) or eggs per 10 ml of urine (for S. haematobium)) or prevalence in
the respective arms 1–3 and the whiskers represent the minimum and maximum infection prevalence or intensity. Sh1, sustaining study in S.
haematobium endemic villages; Sm1, sustaining study in S. mansoni endemic village
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that (i) the prevalence of Schistosoma infection in chil-
dren aged 13–14 years was substantially higher than that
among 9- to 12-year-old children in the same communi-
ties; (ii) differences in sampling methodology between
eligibility and study sample stool assessments; and (iii)
possible random inclusion of atyptical sample of 13- to
14-year-old children with high infection burden in the
eligibility survey but infection level among children in
the study sample were more typical in the 9- to 12-year-
old children leading to regression of average infection
levels towards the mean.
The harmonized protocol for gaining and sustaining
control of schistosomiasis was successfully implemented
in four of the five funded countries. Niger did not allo-
cate interventions to villages as required by the protocol,
but instead grouped study villages by their proximity to
one another – three groups in the sustaining study and
six in the gaining study. These geographically clustered
groups were then randomly assigned to study arms. The
differences in prevalence and intensity in the arms of the
gaining study is a result of this failure to properly ran-
domise at the village level.
Because the data being collected by the Niger team
could not be used to answer the overarching gaining and
sustaining questions, new research questions and a new
study protocol were devised three years into the investi-
gation, to compare the benefits of twice a year PCT
compared with once a year (Fig. 4). In year 3, villages
within each of the original study arms were randomly
assigned to receive PZQ treatment either once or twice
a year in an effort to make use of the two years of data
collection and intervention that had already occurred.
Harmonization of data collection and management ef-
forts across study teams and regions proved a formidable
challenge. Although SCORE provided a list of variables to
be collected and put forth specific forms, for example, for
village inventory data, these were not universally followed.
SCORE had planned to use mobile data collection and
centralised data storage to ensure consistency; however,
this was more difficult than anticipated. The expected
adaptation of the software and use of the same mobile
data collection tools used in lymphatic filariasis studies
was not possible due to the extensive reprogramming re-
quired to adapt the software and to the evolving and rapid
changes in the tools used for mobile data collection.
SCORE partnered with Imperial College London to de-
velop an application of their EpiCollect® software, but this
took longer than expected and was not ready to be imple-
mented by all sites in time for year 1 data collection. Since
then, use of mobile devices for NTD programme data col-
lection has expanded and advanced, and the ease of de-
veloping applications has increased markedly. Mobile
systems (either EpiCollect or the LINKS system) are
currently being used by four of the five study countries.
Systems for data cleaning and submission to SCORE have
been standardised, with data cleaned in-country, then sub-
mitted to SCORE, where they are reviewed and put into a
standardised format (i.e. SCORE uniform data set (SUDS)).
The uniform data sets are then returned to the originating
country PIs, and can also be combined for multi-country
analyses, as in the current paper.
We anticipate that the optimal PCT strategy for a
given region may, in part, depend on the starting preva-
lence and intensity of infection and contextual local fac-
tors that must be carefully considered in the adoption
for schistosomiasis control. The results of these gaining
and sustaining studies will provide data-driven decision
frameworks for national NTD control programme man-
agers, as well as what should be an invaluable source for
researchers and mathematical modellers. The infrastruc-
ture from this research laid by the SCORE programme
has already contributed to important spin-off efforts,
including schistosome infection modelling [33–36]. Of
note, SCORE-related efforts or support have already
resulted in more than 40 peer-reviewed publications and
one non peer-reviewed white paper (all publications and
Fig. 4 Revised study design for Niger. CWT, community-wide treatment; SBT, school-based treatment
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the white paper can be accessed via the SCORE website,
available on: http://www.score.uga.edu).
Conclusion
World Health Assembly (WHA) resolution number
65.21 of March 2012 encourages the world to move to-
wards elimination of schistosomiasis. Although the gain-
ing and sustaining studies described here mainly focus
on morbidity control by carefully examining different
PCT schemes with PZQ, it is widely agreed that to
achieve the reductions in prevalence and intensity
needed to approach the goal of breaking transmission
(i.e. elimination), enhanced PCT such as more frequent
dosing than once a year, additional interventions, such
as snail control, improvement in water, sanitation and
hygiene (WASH), setting-specific information, education
and communication (IEC), paediatric PZQ formulations
and, possibly, drugs that more effectively kill adult worms
and treat juvenile worms, are necessary [8, 37–44]. The
results of these gaining and sustaining studies, however,
will provide strategic information about how best to
implement PCT and use treatment-related resources in
countries with moderate and high prevalence of infection
at the onset of multi-year treatment interventions.
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